MWNA
ANIK icon

Marshall Wace North America’s Anika Therapeutics ANIK Stock Holding History

Marshall Wace North America’s Portfolio ANIK Stock Details ANIK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-9,139
Closed -$264K – 1142
2020
Q1 		$264K Buy
+9,139
New +$370K ﹤0.01% 864
2017
Q3 		– Sell
-13,756
Closed -$674K – 1233
2017
Q2 		$674K Buy
+13,756
New +$633K ﹤0.01% 1035
2013
Q4 		– Sell
-34,687
Closed -$831K – 686
2013
Q3 		$831K Buy
+34,687
New +$779K 0.03% 375

Other funds holding ANIK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BTW
Boston Trust Walden Boston, Massachusetts $12.2B AUM 12.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Marshall Wace North America's ANIK Position: Q2 2020 in Review

Marshall Wace North America sold out of Anika Therapeutics (ANIK) in Q2 2020, closing a stake of 9,139 shares — an estimated $264K sold.

Marshall Wace North America first reported a position in ANIK in Q3 2013 and held it in 3 quarters. The position peaked at $831K in Q3 2013. 158 funds tracked by Wall St. Rank hold ANIK as of Q2 2020.

  • Marshall Wace North America reported no remaining Anika Therapeutics position as of Q2 2020 after selling out during the quarter.
  • Marshall Wace North America sold 9,139 Anika Therapeutics shares in Q2 2020, an estimated $264K.
  • Marshall Wace North America first reported a position in Anika Therapeutics in Q3 2013 and held it in 3 quarters.
  • Marshall Wace North America's Anika Therapeutics position peaked at $831K in Q3 2013.
  • 158 funds tracked by Wall St. Rank held Anika Therapeutics as of Q2 2020.

Based on Marshall Wace North America's 13F filing for Q2 2020, filed 13 Aug 2020.